Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(40%)
Terminated
1(20%)

Phase Distribution

Ph phase_3
2
40%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Terminated(1)
Other(2)

Detailed Status

unknown2
Active, not recruiting1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (50.0%)
Phase 32 (50.0%)

Trials by Status

active_not_recruiting120%
unknown240%
recruiting120%
terminated120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

NCT03016819
active_not_recruitingphase_1

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

NCT04165330
unknownphase_3

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NCT02584478
unknown

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

NCT05612191
terminatedphase_1

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

NCT02558348

Clinical Trials (5)

Showing 5 of 5 trials
NCT03016819Phase 3

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

Recruiting
NCT04165330Phase 1

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active Not Recruiting
NCT02584478Phase 3

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Unknown
NCT05612191

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

Unknown
NCT02558348Phase 1

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5